logo

Adc Therapeutics (ADCT)



Trade ADCT now with
  Date
  Headline
11/20/2020 7:04:49 AM ADC:FDA Grants Priority Review For Lonca For Treatment Of Relapsed/Refractory Diffuse Large B-cell Lymphoma
11/12/2020 7:04:54 AM ADC Therapeutics Q3 Loss Per Share $0.29; Adj Loss Per Share $0.58
11/3/2020 7:19:39 AM ADC Therapeutics Announces First Patient Dosed With Camidanlumab Tesirine With Pembrolizumab In Phase 1b Trial
10/30/2020 7:23:01 AM Genmab And ADC Therapeutics Announce Amended Agreement For Camidanlumab Tesirine
9/23/2020 9:34:15 PM ADC Therapeutics Announces Pricing Of Upsized Public Offering Of 6 Mln Shares At $34.00/shr
9/17/2020 7:22:08 AM ADC Therapeutics Presents Preliminary Findings From Phase 1b Clinical Trial Of Cami In Advanced Solid Tumors
8/18/2020 7:20:09 AM ADC Therapeutics Q2 Net Loss $126.6 Mln Or $2.01/Shr Vs Loss $23.3 Mln Or $0.49/Shr Last Year
7/6/2020 7:32:56 AM ADC Therapeutics: FDA Lifted Partial Clinical Hold On Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine
6/30/2020 10:43:28 AM ADC Therapeutics Completes $267 Mln IPO
6/12/2020 2:33:20 AM ADC Therapeutics Announces Maturing Data From LOTIS 2, A Pivotal Phase 2 Clinical Trial Of Loncastuximab Tesirine
5/21/2020 7:08:10 AM ADC Therapeutics To Present Interim Clinical Data On Lonca At The Virtual 25th EHA25
1/10/2020 6:06:54 AM ADC Therapeutics Names Joseph Camardo Head Of Medical Affairs